Atossa Therapeutics (ATOS) has received the orphan drug designation from the U.S. Food and Drug Administration for its drug candidate, Z-endoxifen. This designation is for the potential treatment of Duchenne muscular dystrophy, a rare and debilitating condition. The FDA's decision was recently announced on their official website, marking a significant step for Atossa in its development of therapies targeting rare diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.